Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120984 | 0.80 | SMN1; SMN2 (0.46) | MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL3204724 | 0.80 | PPARG (0.64) | PPARGMEN1KMT2ASMN1; SMN2USP2 | |
| SCHEMBL8369870 | 0.80 | SLC16A3 (0.62) | SMN1; SMN2JAK2ALDH1A1LMNATP53 | |
| SCHEMBL8368082 | 0.77 | SLC16A3 (0.56) | SMN1; SMN2JAK2ALDH1A1LMNATP53 | |
| SCHEMBL1739414 | 0.77 | AURKA (0.38) | MEN1KMT2AALDH1A1LMNAHTT | |
| SCHEMBL5110775 | 0.76 | MEN1 (0.38) | PPARGMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8369780 | 0.75 | SLC16A3 (0.52) | SMN1; SMN2JAK2ALDH1A1LMNATP53 | |
| SCHEMBL8364692 | 0.74 | SLC16A3 (0.53) | SMN1; SMN2JAK2ALDH1A1LMNATP53 | |
| SCHEMBL14584213 | 0.74 | KMT2A (0.73) | MEN1KMT2ASMN1; SMN2JAK2ALDH1A1 | |
| SCHEMBL8364695 | 0.74 | LMNA (0.44) | PPARGSMN1; SMN2USP2JAK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885MEN1 3927/4885KMT2A 2787/4885 |
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885MEN1 4517/4885KMT2A 2478/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 30/4885MEN1 3517/4885KMT2A 2989/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885MEN1 3927/4885KMT2A 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.